Taken together these results indicate that it is the loss of functional p53 signalling, rather than the aneuploidy inherent to glioma-derived cell lines, that explains the sensitivity of tumour-initiating mouse neural stem cells to Plk1 inhibitors. This evidence concerns the gene TP53 and glioma.